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Purpose: The purpose of this study was to investigate the fibroblast growth factor receptor 2 (FGFR2) gene in three
Chinese patients with Crouzon syndrome and to characterize the related clinical features.
Methods: A single family underwent complete ophthalmic examinations, and three patients were diagnosed with Crouzon
syndrome. Genomic DNA was extracted from leukocytes of peripheral blood collected from members of the family as
well as from 100 unrelated control subjects from the same population. Exons 8 and 10 of FGFR 2 were amplified by
polymerase chain reaction (PCR) and directly sequenced. We performed ophthalmic examinations, including best-
corrected visual acuity, slit-lamp examination, fundus examination, Pentacam, Goldmann perimetry, and computed
tomography (CT) of the skull.
Results: The three patients were affected with shallow orbits and ocular proptosis, accompanied by mid-face hypoplasia
and craniosynostosis, but had clinically normal hands and feet. A heterozygous FGFR2 missense mutation c.1030G>C
(Ala344Pro) in exon 10 was identified in the affected individuals, but not in any of the unaffected family members or the
normal controls. The mutation we identified has not previously been reported, either in China or abroad.
Conclusions: Although FGFR2 mutations and polymorphisms have been reported in various ethnic groups, especially in
the area of osteology, we report, for the first time, the identification of one new FGFR2 gene mutation in Chinese patients
with Crouzon syndrome.
Crouzon  syndrome  (CS),  characterized  by
craniosynostosis, shallow orbits, ocular proptosis, mid-face
hypoplasia, and a curved, beaklike nose, is an autosomal-
dominant,  inherited  disorder  of  the  most  common
craniosynostosis syndrome [1-6].
Until now, it was known that craniosynostosis bears a
strong link to the fibroblast growth factor receptors (FGFRs).
FGFRs are trans-membrane proteins and their ligand-binding
specificity depends on the third extra-cellular Ig-like domain,
which is subject to alternative splicing that generates a variety
of receptor iso-forms. Three different splice variants, IgIIIa,
IgIIIb, and IgIIIc, have been identified [7-10].
It is known that Crouzon syndrome is usually caused by
mutations in the fibroblast growth factor receptor 2 (FGFR2)
gene, located on chromosome 10q26 [11,12]. Most mutations
have been described in FGFR2 and result in Apert, Crouzon,
Jackson-Weiss,  or  Pfeiffer  syndromes.  Over  50  different
mutations have been described in Crouzon syndrome, with
approximately 95% of the cases having mutations in just two
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exons of the gene, IIIa (8) and IIIc (10), which encode the
extra-cellular immunoglobulin-like III (IgIII) domain of the
protein [7].
This  study  reported  the  mutational  analysis  of  one
Chinese family with Crouzon syndrome at the gene level,
along  with  related  clinical  features,  and  identified  one
heterozygous mutation.
METHODS
The Crouzon syndrome family: Three patients in one Chinese
family (Figure 1) were diagnosed, through the Zhongshan
Ophthalmic  Center,  as  having  Crouzon  syndrome.  We
performed  ophthalmic  examinations,  as  follows:  Visual
acuity  was  examined  using  the  Early  Treatment  Diabetic
Retinopathy  Study  (ETDRS)  chart  (Precision  Vision,  La
Salle,  IL).  An  anterior  segment  photograph  was  obtained
using a BX 900 Slit Lamp (Haag-Streit, Bern, Switzerland).
Anterior segment measurements were taken with Pentacam
HR version 70700 (Oculus, Wetzlar, Germany). In addition,
computed tomography (CT) and physical examinations were
performed to exclude systemic diseases.
Sample collection: The affected family was identified at the
Zhongshan Ophthalmic Center. One hundred subjects who
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1278had  no  diagnostic  features  of  Crouzon  syndrome  were
recruited  from  the  same  population  to  serve  as  normal
controls.  After  informed  consent  was  obtained  from  all
participating individuals, according to the principles of the
Declaration of Helsinki, venous blood samples were collected
for  genomic  DNA  extraction  from  peripheral  blood
leucocytes, using standard protocols.
Mutation detection: Exons 8 and 10 of FGFR2 were amplified
by polymerase chain reaction (PCR) with primers (Table 1)
[13]. Briefly, PCR was conducted in 50-μl reactions. The
cycling profile included one cycle at 94 °C for 5 min, followed
by 40 cycles at 94 °C for 45 s, 52–66 °C for 45 s, and 72 °C
for 45 s, as well as one cycle at 72 °C for 10 min. The PCR
products  were  sequenced  from  both  directions  with  an
ABI3730 Automated Sequencer (PE Biosystems, Foster City,
CA). The sequencing results were analyzed using Chromas
(version  2.3;  Technelysium  Pty  Ltd,  Brisbane,  QLD,
Australia); they were compared with the reference sequences
in  the  database  at  the  National  Center  for  Biotechnology
Information (NCBI; NC_000010.10).
RESULTS
Clinical data: The Chinese family studied in this report was
from the southern area of China. Three individuals, in two
successive  generations,  were  found  to  have  the  same
congenital  disease  (Figure  1).  These  patients  had  shallow
orbits  and  ocular  proptosis,  accompanied  by  mid-face
hypoplasia, craniosynostosis, a curved, beaklike nose, but
clinically  normal  hands  and  feet.  Although  they  had  had
normal  vision  since  early  childhood,  just  displaying  a
surprised look, their vision was getting worse and worse as
they aged (Figure 2A,B).
The I-2 patient (52 years old; female) had already had
eyeball  extraction  surgery  because  of  serious  exposure
keratitis, corneal scarring and serious eye pain. As a result, we
don’t have the pictures and examination results for her.
The visual acuity of the II-2 patient (22 years old; male),
as  measured  by  logarithm  of  the  minimum  angle  of
resolution(Log MAR), was LP (light perception, OD) and
NLP (no light perception, OS). The cornea of the right eye had
very serious exposure keratitis (Figure 2A) and the left eye
had  chronic  corneal  scarring  (Figure  2B),  with  no  light
perception. No abnormalities were detected in the lens, retina,
choroid, or optic nerve of the left eye, and we were unable to
examine the lens, retina, choroid, and optic nerve of the right
eye, or the axial length and the eye prominence, because of
the serious corneal scar and the keratitis.
Figure 2C shows the right eye of the II-4 patient (10 years
old; female). She had shallow orbits and ocular proptosis,
accompanied  by  mid-face  hypoplasia  (Figure  2D)  and
clinically normal hands and feet. The visual acuity of the II-4
patient was 0.7 (OD) and 0.4 (OS). The refractive error of the
II-2 patient was −1.75D, with −1.50 astigmatism (OD) and
−1.25D, with −1.50 astigmatism (OS). Axial lengths were
24.54 mm (OD) and 24.42 mm (OS). No abnormalities were
Figure  1.  The  pedigree  of  a  Chinese
family with Crouzon syndrome. Squares
denote  males  and  circles  denote
females. The shaded symbols indicate
ophthalmologist-confirmed  Crouzon
syndrome.  The  arrow  points  to  the
proband.
TABLE 1. PRIMERS USED FOR PCR.
Exon Forward (5′-3′) Reverse (5′-3′) Product
size (bp)
Annealing
temperature
(°C)
FGFR2–8 (IIIa) GGTCTCTCATTCTCCCATCCC CCAACAGGAAATCAAAGAACC 325 61
FGFR2–10 (IIIc) CCTCCACAATCATTCCTGTGTC ATAGCAGTCAACCAAGAAAAGGG 257 61
          Summary of the primers and products length used for the amplification of the exons of FGFR2.
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1279detected in the lenses, retinas, choroids, or optic nerves. The
anterior  segment  photograph  is  shown  in  Figure  2E;  the
anterior chamber depths were 3.15 mm (OD) and 3.17 mm
(OS). The prominence of the II-5 patient was 17 mm (OD)
and 16 mm (OS).
Mutation screening: A heterozygous missense mutation c.
1030G>C in exon 10 of FGFR2 (Figure 3) was identified in
the three affected individuals, but not in any of the unaffected
family members, nor in the normal controls. The mutation
causes the Alanine 344 codon (GCG) to change to a Proline
codon (CCG).
DISCUSSION
In this study, we found one mutation in exon 10 of FGFR2
that is associated with Crouzon Syndrome: c.1030G>C. This
mutation,  rather  than  a  rare  polymorphism  in  the  normal
population, is the causative mutation in the family.
The c.1030G>C mutation (Ala344Pro) was identified, for
the  ﬁrst  time,  in  FGFR2  in  Chinese  patients;  it  has  not
previously been reported either in China or abroad.
Previously described mutations causing craniosynostosis
are  widely  distributed  across  the  FGFR2  protein,  yet  the
majority localize in some amino acids that form the S-S bond
Figure 2. Examination results of Patients II-2 and II-4. A: The anterior segment photograph of the right eye of Patient II-2. The cornea had
serious exposure keratitis. B: The anterior segment photograph of the left eye of Patient II-2. The cornea was opaque. C: The anterior segment
picture of Patient II-4. D: Ocular proptosis of Patient II-4. E: The anterior segment picture of Patient II-4 by Pentacam.
Figure 3. DNA sequence of a part of the
FGFR2 gene in the affected patients and
unaffected individuals. A heterozygous
missense mutation c.1030G>C in exon
10 was identified in the three affected
individuals,  but  not  in  any  of  the
unaffected  family  members  or  the
normal controls. The mutation causes
the Alanine 344 codon (GCG) to change
to a Proline codon (CCG).
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protein’s  structure,  dimerization,  and  activation  of  the
receptor [14].
The ocular manifestations in the conditions caused by
FGFR mutations included down-slanting palpebral fissures,
shallow  orbits  and  proptosis,  hypertelorism,  strabismus,
ocular anterior chamber dysgenesis, optic nerve hypoplasia,
scleralization  of  the  cornea,  and  corectopia  in
craniosynostosis  syndromes  [15-17].  In  addition,  the
syndrome gets worse and worse with aging because of the
exposure  keratitis,  which  suggests  that  a  suitable  orbital
decompression  surgery  at  a  reasonable  time  is  of  vital
importance, to prevent the progress of Crouzon syndrome.
Until now, Crouzon syndrome has generally been treated
by  Le  Fort  III  advancement  osteotomies,  followed  by
distraction  [18,19].  Quadrangular  osteotomy,  which  is
specifically  designed  to  correct  maxillary  hypoplasia
extending to the infra-orbital rim, has also been performed.
The  infra-orbital  rim  can  be  moved  forward,  thereby
improving exorbitism, but the nasion and posterior zygomatic
arch  cannot  be  changed  [18,20].  In  our  patient  II-2,  we
performed a quadrangular osteotomy with midline split to
simultaneously  achieve  anterior  advancement  and  lateral
expansion. This combination of anterior and lateral distraction
may enable us to obtain a suitable orbital space.
In summary, this study identified one novel mutation of
FGFR2 in a Chinese family with Crouzon syndrome. This
finding  expands  the  mutation  spectrum  of  FGFR2  and  is
useful  and  valuable  for  genetic  counseling  and  prenatal
diagnosis in families with Crouzon syndrome without serious
ocular disorders.
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